Immunological Reaction of the Recipient After Cold-stored Saphenous Venous Allograft (Bioprotec)

Centre Hospitalier Universitaire de Nīmes50 enrolled

Overview

The study investigators propose to perform a blood test before and after allograft placement in all patients receiving a cold-stored venous allografts at the University Hospital of Nîmes to study the occurrence of FVFA-related ASD in these patients. The aim of this work is to characterize a possible immune reaction generated by the implantation of venous allografts prepared according to the BIOPROTEC method. In case of a proven immune reaction, the study will allow a modification of our current attitude and to exclude patients potentially eligible for renal transplantation at the time of venous allograft placement, or to perform in these patients an allo-compatibility test with the venous allograft preoperatively and thus protect these patients from an increased risk of subsequent organ transplant rejection.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Allograft Cold Temperature Saphenous Vein

Interventions

Blood test

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * The patient must be a member or beneficiary of a health insurance plan * Patients receiving a scheduled venous allograft within the CHU of Nîmes for an arterial bypass in the lower limb or an arteriovenous bypass in the upper limb within the framework of the creation of arteriovenous fistulas in dialysis patients, in the absence of available autologous venous material. Exclusion Criteria: * The subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study * The subject has already been included in the study * The subject refuses to participate * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship * Patient previously having received a venous allograft or organ transplant * Pregnant, parturient or breastfeeding patients

Outcomes

Primary Outcomes

Presence of donor specific antibodies after venous allograft

Presence/absence of donner anti-HLA antibodies in patient blood, detected using Luminex assay

Time frame: 1 month

Secondary Outcomes

Allograft anomalies linked to allograft rejection

Inflammation, thrombosis, aneurysms progression